 |
1 Product |  |
110 Diseases | | 1 Product |
|
1 Trial |  |
94 News |  |
| 12» |
- || CT011 / CARsgen
New P1 trial, CAR T-Cell Therapy: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection (clinicaltrials.gov) - Aug 18, 2024
P1, N=30, Recruiting, Sponsor: CARsgen Therapeutics Co., Ltd.
- | pidilizumab (CT-011) / CureTech
Trial completion date, Trial primary completion date: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Jun 11, 2024
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Sep 2024
- Adrenal insufficiency in patients on immune checkpoint inhibitors: () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4689;
Future prospective studies will be needed to confirm this finding. Physicians, particularly oncologists and endocrinologists, should have a high index of suspicion for adrenal insufficiency in patients on immune checkpoint inhibitors.
- | pidilizumab (CT-011) / CureTech
Trial primary completion date, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Sep 8, 2022
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Physicians, particularly oncologists and endocrinologists, should have a high index of suspicion for adrenal insufficiency in patients on immune checkpoint inhibitors. Trial primary completion date: Jul 2022 --> Jul 2023
- | pidilizumab (CT-011) / CureTech
Journal: Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. (Pubmed Central) - Aug 24, 2022
The unprecedented structural data on Pidilizumab's interactions provided novel evidence that its legitimate target is the DLL1 protein and offered structural insight on how these molecules interact, shedding light on the pathways that could be affected by the use of this essential immunobiological. Communicated by Ramaswamy H. Sarma.
- || pidilizumab (CT-011) / CureTech
So what became of the Teva/Curetech CT-011. Quick search suggests deal was terminated in 2014, Curetech was acquired by InSight Biopharma in 2018 which was itself bought by Gencor Pacific in 2019. No trace since? (Twitter) - May 10, 2022
- |||| pidilizumab (CT-011) / CureTech, Retevmo (selpercatinib) / Eli Lilly
Clinical, Pan tumor: Tissue agnostic including GI malignancies 👉Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers @MPishvaian @doctorpemm @weldeiry #TumorBoardTuesday https://t.co/jhymEwtORo (Twitter) - Sep 29, 2021
- | pidilizumab (CT-011) / CureTech
Trial completion date, Trial primary completion date, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Aug 18, 2021
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Communicated by Ramaswamy H. Sarma. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
- || SYN023 / Synermore
Clinical, P1 data, PK/PD data, Journal, Combination therapy: Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects. (Pubmed Central) - Jul 28, 2021
The clinical trial registration number is CTR20190281. http://www.chinadrugtrials.org.cn/eap/clinicaltrials.searchlist?a=a®_no=CTR20190281.
- | pidilizumab (CT-011) / CureTech
Trial primary completion date, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Dec 22, 2020
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
http://www.chinadrugtrials.org.cn/eap/clinicaltrials.searchlist?a=a®_no=CTR20190281. Trial primary completion date: Dec 2019 --> Jul 2021
- Talzenna (talazoparib) / Pfizer, temozolomide / Generic mfg.
The combination of PARP inhibitor talazoparib with low-dose temozolomide results in increased cell lethality in BRCA1/2 wild-type melanoma, small cell lung cancer, ovarian, and colon cancer cell lines and mouse xenografts via the formation of DNA double-strand breaks during S-phase (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2463;
Taking into consideration both the molecular data demonstrating efficacy of talazoparib plus temozolomide therapy in BRCA1/2 wild-type cell lines and mouse xenografts and the Phase I trial data showing safety and efficacy with this combination, PARP inhibitors likely have utility beyond treatment of gBRCA1/2+ patients. Use of the alkylating agent might be particularly important, as it is recognized during S-phase and trapping of PARP on the DNA could result in collapse of a stalled replication fork into a DNA double-strand break.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Clinical, Review, Journal, IO Biomarker: Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence. (Pubmed Central) - Aug 22, 2019
To this end, our article provides a structured approach for standardized selection and reporting of imaging modalities to enable the use of precision medicine by deciphering the characteristics of the tumor and its immune environment. Emerging preclinical or clinical innovations are also discussed as future directions such as immune-specific targeting and implementation of artificial intelligence algorithms.
- || pidilizumab (CT-011) / CureTech
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 30, 2019
P1/2, N=20, Completed, Sponsor: Yvonne Efebera
Emerging preclinical or clinical innovations are also discussed as future directions such as immune-specific targeting and implementation of artificial intelligence algorithms. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> May 2019 | Trial primary completion date: Dec 2019 --> May 2019
- | pidilizumab (CT-011) / CureTech
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 18, 2019
P1/2, N=20, Active, not recruiting, Sponsor: Yvonne Efebera
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> May 2019 | Trial primary completion date: Dec 2019 --> May 2019 Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019
- | pidilizumab (CT-011) / CureTech
Enrollment change, Trial termination: Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission (clinicaltrials.gov) - Mar 19, 2018
P2, N=4, Terminated, Sponsor: Northwestern University
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019 N=30 --> 4 | Active, not recruiting --> Terminated; sponsor decided to discontinue development of the study drug.
- pidilizumab (CT-011) / CureTech
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 6, 2017
P1/2, N=20, Active, not recruiting, Sponsor: Yvonne Efebera
N=30 --> 4 | Active, not recruiting --> Terminated; sponsor decided to discontinue development of the study drug. Trial primary completion date: Jun 2017 --> Jun 2018
- | pidilizumab (CT-011) / CureTech, Provenge (sipuleucel-T) / Bausch Health
Enrollment change, Trial termination: Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer (clinicaltrials.gov) - Sep 18, 2017
P2, N=7, Terminated, Sponsor: Augusta University
Trial primary completion date: Jun 2017 --> Jun 2018 N=57 --> 7 | Suspended --> Terminated; Drug supply issues
- | pidilizumab (CT-011) / CureTech
Enrollment change, Trial termination, Trial primary completion date, PD(L)-1 Biomarker: Gemcitabine and CT-011 for Resected Pancreatic Cancer (clinicaltrials.gov) - Sep 18, 2017
P2, N=2, Terminated, Sponsor: Augusta University
N=57 --> 7 | Suspended --> Terminated; Drug supply issues N=29 --> 2 | Suspended --> Terminated | Trial primary completion date: Feb 2018 --> Jan 2017; Drug supply issues
- | pidilizumab (CT-011) / CureTech
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Jul 4, 2017
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
N=29 --> 2 | Suspended --> Terminated | Trial primary completion date: Feb 2018 --> Jan 2017; Drug supply issues Trial primary completion date: Dec 2016 --> Dec 2018
- | pidilizumab (CT-011) / CureTech
Enrollment closed, Enrollment change, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 7, 2017
P1/2, N=20, Active, not recruiting, Sponsor: Yvonne Efebera
Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Active, not recruiting | N=53 --> 20
- pidilizumab (CT-011) / CureTech
Enrollment closed, Enrollment change: Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission (clinicaltrials.gov) - Jan 5, 2017
P2, N=30, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting | N=53 --> 20 Recruiting --> Active, not recruiting | N=150 --> 30
- pidilizumab (CT-011) / CureTech
Enrollment change, Trial withdrawal: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Nov 25, 2016
P2, N=0, Withdrawn, Sponsor: Medivation, Inc.
Recruiting --> Active, not recruiting | N=150 --> 30 N=180 --> 0 | Not yet recruiting --> Withdrawn
- pidilizumab (CT-011) / CureTech
Enrollment closed: Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Sep 13, 2016
P1/2, N=50, Active, not recruiting, Sponsor: Hadassah Medical Organization
N=180 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- ||| pidilizumab (CT-011) / CureTech
Trial initiation date: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Aug 30, 2016
P2, N=180, Not yet recruiting, Sponsor: Medivation, Inc.
Recruiting --> Active, not recruiting Initiation date: Mar 2016 --> Dec 2016
- Dendritic cell renal cell carcinoma fusion vaccine / Beth Israel Deaconess Medical Center
Enrollment closed, Trial primary completion date: PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine (clinicaltrials.gov) - Jul 19, 2016
P2, N=44, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Initiation date: Mar 2016 --> Dec 2016 Completed --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Sep 2016
- pidilizumab (CT-011) / CureTech
Trial primary completion date, PD(L)-1 Biomarker: Gemcitabine and CT-011 for Resected Pancreatic Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=29, Suspended, Sponsor: Georgia Regents University
Completed --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Sep 2016 Trial primary completion date: Feb 2016 --> Feb 2018
- pidilizumab (CT-011) / CureTech, Provenge (sipuleucel-T) / Bausch Health
Trial suspension: Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=57, Suspended, Sponsor: Georgia Regents University
Trial primary completion date: Feb 2016 --> Feb 2018 Recruiting --> Suspended
- |||| pidilizumab (CT-011) / CureTech
Enrollment open, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=53, Recruiting, Sponsor: Yvonne Efebera
Recruiting --> Suspended Suspended --> Recruiting
- Dendritic cell renal cell carcinoma fusion vaccine / Beth Israel Deaconess Medical Center
Trial completion, Trial primary completion date: PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine (clinicaltrials.gov) - Apr 14, 2016
P2, N=44, Completed, Sponsor: Beth Israel Deaconess Medical Center
Suspended --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Apr 2016
- ||| pidilizumab (CT-011) / CureTech
Trial initiation date: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 11, 2016
P2, N=180, Not yet recruiting, Sponsor: Medivation, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Apr 2016 Initiation date: Nov 2015 --> Mar 2016
- | pidilizumab (CT-011) / CureTech
Trial suspension, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 26, 2016
P1/2, N=53, Suspended, Sponsor: Yvonne Efebera
Initiation date: Nov 2015 --> Mar 2016 Recruiting --> Suspended
- pidilizumab (CT-011) / CureTech
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Jan 22, 2016
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Suspended Trial primary completion date: Jun 2016 --> Dec 2016
- Dendritic cell renal cell carcinoma fusion vaccine / Beth Israel Deaconess Medical Center
Trial primary completion date: PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine (clinicaltrials.gov) - Jan 19, 2016
P2, N=44, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Nov 2015 --> Nov 2016
- ||||| pidilizumab (CT-011) / CureTech
New P2 trial: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 15, 2016
P2, N=180, Recruiting, Sponsor: Medivation, Inc.
- pidilizumab (CT-011) / CureTech
Enrollment change, Trial primary completion date: Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Nov 5, 2015
P1/2, N=50, Recruiting, Sponsor: Hadassah Medical Organization
Trial primary completion date: Nov 2015 --> Nov 2016 N=30 --> 50 | Trial primary completion date: Nov 2015 --> Nov 2018
- pidilizumab (CT-011) / CureTech
Enrollment open: Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission (clinicaltrials.gov) - Sep 18, 2015
P2, N=150, Recruiting, Sponsor: Northwestern University
N=30 --> 50 | Trial primary completion date: Nov 2015 --> Nov 2018 Not yet recruiting --> Recruiting
- pidilizumab (CT-011) / CureTech
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Sep 1, 2015
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Jun 2016
- | pidilizumab (CT-011) / CureTech
New P2 trial: Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission (clinicaltrials.gov) - Aug 20, 2015
P2, N=150, Not yet recruiting, Sponsor: Northwestern University
- pidilizumab (CT-011) / CureTech
Trial suspension, PD(L)-1 Biomarker: Gemcitabine and CT-011 for Resected Pancreatic Cancer (clinicaltrials.gov) - Jul 16, 2015
P2, N=29, Suspended, Sponsor: Georgia Regents University
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Suspended
- pidilizumab (CT-011) / CureTech
Trial initiation date: Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Apr 21, 2015
P1/2, N=30, Recruiting, Sponsor: Hadassah Medical Organization
Recruiting --> Suspended Initiation date: Nov 2013 --> Feb 2014
- | pidilizumab (CT-011) / CureTech, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date, Combination therapy: Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma (clinicaltrials.gov) - Apr 9, 2015
P2, N=32, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Nov 2013 --> Feb 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2015
- Dendritic cell renal cell carcinoma fusion vaccine / Beth Israel Deaconess Medical Center
Enrollment closed: PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine (clinicaltrials.gov) - Sep 16, 2014
P2, N=44, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2015 Recruiting --> Active, not recruiting
- pidilizumab (CT-011) / CureTech
Trial termination: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection (clinicaltrials.gov) - Aug 29, 2014
P1/2, N=13, Terminated, Sponsor: CureTech Ltd
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- pidilizumab (CT-011) / CureTech, Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date: Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=57, Recruiting, Sponsor: Georgia Regents University
Active, not recruiting --> Terminated Trial primary completion date: Dec 2014 --> Dec 2016
- pidilizumab (CT-011) / CureTech
Trial primary completion date, PD(L)-1 Biomarker: Gemcitabine and CT-011 for Resected Pancreatic Cancer (clinicaltrials.gov) - Aug 15, 2014
P2, N=29, Recruiting, Sponsor: Georgia Regents University
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Feb 2014 --> Feb 2016
- pidilizumab (CT-011) / CureTech
Enrollment closed, PD(L)-1 Biomarker, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Aug 7, 2014
P2, N=35, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Feb 2014 --> Feb 2016 Recruiting --> Active, not recruiting
- pidilizumab (CT-011) / CureTech
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (clinicaltrials.gov) - Jun 12, 2014
P2, N=35, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jun 2015
- ||||| pidilizumab (CT-011) / CureTech
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker: Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 2, 2014
P1/2, N=53, Recruiting, Sponsor: Yvonne Efebera
- pidilizumab (CT-011) / CureTech
Enrollment open: Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Feb 25, 2014
P1/2, N=30, Recruiting, Sponsor: Hadassah Medical Organization
Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- pidilizumab (CT-011) / CureTech
Enrollment open, PD(L)-1 Biomarker: Gemcitabine and CT-011 for Resected Pancreatic Cancer (clinicaltrials.gov) - Oct 14, 2013
P2, N=29, Recruiting, Sponsor: Georgia Regents University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting